[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT06033196":3,"trial-entities:NCT06033196":381,"trial-summary:NCT06033196":386},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":20,"study_type":24,"primary_purpose":25,"phases":26,"enrollment_info":28,"interventions":31,"primary_outcomes":43,"secondary_outcomes":48,"sex":100,"minimum_age":101,"maximum_age":102,"healthy_volunteers":103,"eligibility_criteria":104,"std_ages":108,"locations":112,"central_contacts":354,"overall_officials":359,"references":371,"see_also_links":372},"NCT06033196","DAIT CTOT-45","Tocilizumab in Lung Transplantation","Targeting Inflammation and Alloimmunity in Lung Transplant Recipients With Tocilizumab (CTOT-45)","RECRUITING","2029-01-08","2026-08","2026-08-10","2024-02-13","National Institute of Allergy and Infectious Diseases (NIAID)","NIH",true,"This is a trial in which 350 primary lung transplant recipients will be randomized (1:1) to receive either Tocilizumab (six doses over 20 weeks) plus standard triple maintenance immunosuppression or placebo (sterile normal saline) plus standard triple maintenance immunosuppression (Tacrolimus, Mycophenolate Mofetil, corticosteroids).\n\nThe primary objective is to test the hypothesis that treatment with triple maintenance immunosuppression plus Tocilizumab (TCZ) is superior to triple maintenance immunosuppression plus placebo (saline) as defined by a composite endpoint of a) CLAD, b) listed for re-transplantation, and c) death",null,[19],"Lung Transplant",[19,21,22,23],"Tocilizumab","Immunosuppression","ACTEMRA","INTERVENTIONAL","TREATMENT",[27],"PHASE2",{"count":29,"type":30},350,"ESTIMATED",[32,38],{"type":33,"name":21,"description":34,"armGroupLabels":35,"otherNames":37},"DRUG","The initial dose of tocilizumab will be administered in the operating room before reperfusion of the first lung during the lung transplant surgery.\n\n6 doses will be given once every four weeks over a 20-week period. The dose is approved for pediatric patients who weigh 30 kg or more",[36],"Tocilizumab Group",[23],{"type":33,"name":39,"description":40,"armGroupLabels":41},"Placebo for Tocilizumab","Placebo 0.9% Sodium Chloride Injection USP (Normal Saline)\n\nPlacebo will be given as a single intravenous dose, volume matched to tocilizumab. Placebo will be administered over a period of approximately 60 minutes; once every four weeks over a 20-week period. The first placebo dose will be during the transplant surgery before reperfusion of the first lung allograft, with 5 subsequent monthly doses",[42],"Placebo Group",[44],{"measure":45,"description":46,"timeFrame":47},"Proportion of subjects who meet any one of the pre-specified events detailed in the outcome description: from Baseline up to 36 months","1. The development of Chronic Lung Allograft Dysfunction (CLAD)\n\n   * The development of any form of CLAD will be defined according to the standard 2019 The International Society for Heart and Lung Transplantation (ISHLT) criteria.\n2. Listed for re-transplantation\n\n   * Re-transplantation defined as the subject has been formally registered on the United Network for Organ Sharing (UNOS) waiting list to undergo a second lung transplant surgery\n3. Death\n\n   * Primary analysis will be conducted according to an Intent-to-treat (ITT) principle and therefore will include all randomized subjects who receive Tocilizumab(TCZ) or placebo. The time from randomization to development of CLAD will be compared between the two treatment groups (TCZ vs. placebo) using a Pearson's chi-square test.","Over a period of 3 years after randomization",[49,52,54,56,58,61,64,66,68,70,72,74,76,78,80,82,84,86,88,90,92,94,96,98],{"measure":50,"timeFrame":51},"Time to the onset of CLAD, being listed for re-transplantation, or death","At 3 years after randomization",{"measure":53,"timeFrame":51},"Cumulative incidence of Chronic Lung Allograft Dysfunction (CLAD)",{"measure":55,"timeFrame":51},"Cumulative incidence listed for re-transplantation",{"measure":57,"timeFrame":51},"Cumulative incidence of death",{"measure":59,"description":60,"timeFrame":51},"Freedom from Acute Cellular Rejection (ACR) grade >=A2","Transbronchial lung biopsies will be performed according to the local center standard of care using the 2007 International Society for Heart and Lung Transplantation (ISHLT) criteria.\n\nAcute Cellular Rejection (A grade Rejection) Scale:\n\n* None (A0)\n* Minimal (A1)\n* Mild (A2)\n* Moderate (A3)\n* Severe (A4)\n* Ungradable (AX)",{"measure":62,"description":63,"timeFrame":51},"Proportion of subjects free from Antibody Mediated Rejection (AMR)","Antibody mediated rejection studies will be performed using original H\\&E stained slides, trichrome\u002Felastic trichrome stain, and C4d immunostain (5 slides per case), along with positive controls",{"measure":65,"timeFrame":51},"Proportion of subjects free from the development of de novo donor specific antibodies (dnDSA)",{"measure":67,"timeFrame":51},"Incidence of Gastrointestinal (GI) tract perforation",{"measure":69,"timeFrame":51},"Incidence of serious infections requiring intravenous antimicrobial therapy and need for hospitalization",{"measure":71,"timeFrame":51},"Incidence of confirmed bacterial infection requiring antimicrobial therapy",{"measure":73,"timeFrame":51},"Incidence of confirmed Cytomegalovirus (CMV) infection requiring antimicrobial therapy",{"measure":75,"timeFrame":51},"Incidence of confirmed mold infection requiring antimicrobial therapy",{"measure":77,"timeFrame":51},"Incidence of confirmed mycobacterial infection requiring antimicrobial therapy",{"measure":79,"timeFrame":51},"Incidence of confirmed community-acquired respiratory viral infection, including coronavirus disease 2019 (COVID-19) infection",{"measure":81,"timeFrame":51},"Incidence of discontinuation of Tocilizumab (TCZ) due to an adverse event",{"measure":83,"timeFrame":51},"Incidence of discontinuation of Tocilizumab (TCZ) due to serious adverse event",{"measure":85,"timeFrame":51},"Incidence of discontinuation of Tocilizumab (TCZ) placebo due to an adverse event",{"measure":87,"timeFrame":51},"Incidence of discontinuation of Tocilizumab (TCZ) placebo due to serious adverse event",{"measure":89,"timeFrame":51},"Incidence of malignancy excluding squamous or basal cell skin cancer",{"measure":91,"timeFrame":51},"Incidence of Tuberculosis (TB)",{"measure":93,"timeFrame":51},"Incidence of Post-transplant lymphoproliferative disorder (PTLD)",{"measure":95,"timeFrame":51},"Time to the onset of Chronic Lung Allograft Dysfunction (CLAD)",{"measure":97,"timeFrame":51},"Time to the onset of being listed for re-transplantation",{"measure":99,"timeFrame":51},"Time to the onset of death","ALL","12 Years","75 Years",false,{"inclusion":105,"exclusion":106,"raw_text":107},[],[],"Inclusion Criteria:\n\nStudy Entry:\n\n1. Subject and\u002For parent guardian must be able to understand the purpose of the study and willing to participate and sign informed consent\u002Fassent\n2. Greater than or equal to 30 kg body weight\n3. Listed or received for a primary lung transplant\n4. No previous or planned desensitization therapy prior to transplant\n5. Serum Immunoglobulin G (IgG) level greater than 400 mg\u002FdL. Patients treated with intravenous immune globulin (IVIG) for hypogammaglobulinemia are eligible for enrollment if their serum IgG level is greater than 400 mg\u002FdL 14 or more days after the most recent IVIG treatment\n6. For women of child-bearing potential, willingness to use highly-effective contraception; according to the Food and Drug Administration (FDA) Office of Women's Health (http:\u002F\u002Fwww.fda.gov\u002Fbirthcontrol).\n\n   Female participants of child-bearing potential must consult with their physician and determine the most suitable method(s) from this list to be used for the duration of the study. Those who choose oral contraception must agree to use a second form of contraception after administration of study drug for a period of 1 year after the last dose of study drug\n7. Tested negative for latent TB infection (LTBI) using a PPD or interferon-gamma release assay (i.e., QuantiFERON-TB, T-SPOT.TB) within 1 year prior to transplant or has completed appropriate LTBI therapy within the 1 year prior to transplant\n8. Vaccinations must be up to date per the Division of Allergy, Immunology, and Transplantation (DAIT) Guidance for Patients in Transplant Trials\n\nRandomization:\n\n1. Provide written informed consent for the study participation, and agree to continue in the study\n2. Received a single or bilateral lung transplant\n3. Agreement to use contraception; according to the FDA Office of Women's Health (http:\u002F\u002Fwww.fda.gov\u002Fbirthcontrol), there are a number of birth control methods that are more than 80% effective. Female participants of child-bearing potential must consult with their physician and determine the most suitable method(s) from this list to be used for the duration of the study. Those who choose oral contraception must agree to use a second form of contraception after administration of study drug for a period of 1 year after the last dose of study drug\n4. Negative physical crossmatch at the time of transplant or a crossmatch result that did not require specific treatment per the site's clinical protocol\n5. Underwent bronchoscopy and found to have satisfactory bronchial anastomotic healing\n6. No desensitization therapy prior to transplant\n7. Negative pregnancy test (serum or urine) for women of child-bearing potential within 48 hours prior to randomization\n8. Recipient of lungs that have been supported with ex vivo lung perfusion (EVLP) devices are permitted\n\nExclusion Criteria:\n\nStudy Entry:\n\n1. Listed for multi-organ transplant (e.g., heart-lung, liver-lung, kidney-lung)\n2. Prior history of allogeneic organ or cellular transplantation\n3. Received treatment to deplete Human Leukocyte Antigens (HLA) antibodies before transplantation\n4. Currently breast-feeding a child or plans to become pregnant during the timeframe of the study follow up period\n5. History of severe allergic and\u002For anaphylactic reactions to humanized or murine monoclonal antibodies\n6. Known hypersensitivity or previous treatment with ACTEMRA(R) (tocilizumab) within the last 3 months\n7. Infection with human immunodeficiency virus (HIV)\n8. Hepatitis B virus surface antigen or core antibody positive\n9. Hepatitis C virus PCR positive (HCV+) patients who have failed to demonstrate sustained viral remission (2 consecutive PCR or Nucleic Acid Tests (NAT) negative tests at least 24 weeks apart), with or without anti-viral treatment;\n10. Chronic infection with Burkholderia cenocepacia or Burkholderia gladioli\n11. Non-tuberculous mycobacterial (NTM) pulmonary disease; if there is a history of NTM pulmonary disease, culture conversion is necessary for eligibility\n12. Presence of active malignancy or history of malignancy less than 5 years in remission, excluding adequately treated in-situ cervical carcinoma, low grade prostate carcinoma, or adequately treated basal or squamous cell carcinoma of the skin\n13. History of hemolytic-uremic syndrome\u002F thrombotic thrombocytopenia purpura\n14. History of demyelinating disorders (e.g., multiple sclerosis, chronic inflammation demyelinating polyneuropathy)\n15. Current treatment with alkylating agents such as cyclophosphamide\n16. History of gastrointestinal (GI) tract perforation\n17. History of inflammatory bowel disease except fully excised ulcerative colitis\n18. Any history of diverticulitis (event if not perforated) or confirmed diverticular bleeding. (Diverticulosis is not an exclusion).\n19. Patients with a platelet count \\\u003C 100,000\u002Fmm\\^3 (last measurement within 7 days prior to enrollment)\n20. Patients with an absolute neutrophil count (ANC) \\\u003C 2,000\u002Fmm\\^3 (last measurement within 7 days prior to enrollment)\n21. Patients with Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) levels \\>3 times upper limit of normal\n22. Patients who use illegal drugs\n23. Smoking or vaping within 6 months of listing for transplant\n24. Use of investigational drugs within 4 weeks prior to enrollment\n25. Any condition that in the opinion of the site Principal Investigator (PI) introduces undue risk by participating in this study\n\nRandomization:\n\n1. Recipient of multi-organ or tissue transplants\n2. Clinically stable, without clinical evidence of untreated infection\n3. Received a live virus vaccine within 30 days prior to randomization\n4. Received treatment to deplete HLA antibodies before transplantation to improve the possibility of transplantation\n5. Patients with known donor-specific antibody that will require intervention based on local clinical protocols\n6. History of GI tract perforation\n7. History of inflammatory bowel disease except fully excised ulcerative colitis\n8. History of diverticulitis (diverticulosis is not an exclusion) or diverticular bleeding\n9. History of severe allergic anaphylactic reactions to humanized or murine monoclonal antibodies\n10. Known hypersensitivity to ACTEMRA® (tocilizumab)\n11. Previous treatment with ACTEMRA® (tocilizumab) within the last 3 months.\n12. Recipient or donor with infection with human immunodeficiency virus (HIV)\n13. Recipient with hepatitis B virus surface antigen or hepatitis B core antibody positive\n14. Hepatitis B negative transplant recipient that received a transplant from a Hepatitis B core antibody positive donor unless the recipient has a Hepatitis B Surface Antigen (HBsAb) titer \\>10U\u002FL\n15. Recipient of a hepatitis C virus nucleic acid test (NAT) positive donor organ\n16. Latent TB infection (LTBI) and has not completed appropriate therapy\n17. Chronic infection with Burkholderia cenocepacia or Burkholderia gladioli\n18. Non-tuberculous mycobacterial (NTM) pulmonary disease; if there is a history of NTM pulmonary disease, culture conversion is necessary for eligibility\n19. Presence of active malignancy (except for non-melanoma skin cancer)\n20. History of hemolytic-uremic syndrome\u002F thrombotic thrombocytopenia purpura\n21. History of demyelinating disorders (e.g., multiple sclerosis, chronic inflammation demyelinating polyneuropathy)\n22. Current treatment with alkylating agents such as cyclophosphamide\n23. Patients with AST or ALT levels \\> 1.5 times upper limit of normal (last measurement within 1 day prior to randomization)\n24. Patients with platelet count \\\u003C100,000\u002Fmm\\^3 (last measurement within 1 day prior to randomization)\n25. Patients with an absolute neutrophil count (ANC) \\\u003C2,000\u002Fmm\\^3 (last measurement within 1 day prior to randomization)\n26. Patients who are administered anti-thymocyte globulin as induction therapy in the immediate post- transplant period\n27. Patients who have been treated in the past 3 months, or for whom it is anticipated that treatment with any immunomodulatory biological agents post-transplant are excluded\n28. Use of an investigational drug after transplant\n29. Smoking or vaping since enrollment\n30. Any condition that in the opinion of the site PI introduces undue risk by participating in this study",[109,110,111],"CHILD","ADULT","OLDER_ADULT",[113,128,141,153,167,180,189,202,206,218,231,234,246,259,272,284,297,310,323,330,341],{"facility":114,"status":8,"city":115,"state":116,"zip":117,"country":118,"contacts":119,"geoPoint":125},"St. Joseph's Hospital and Medical Center (Site #: 71192)","Phoenix","Arizona","85013","United States",[120],{"name":121,"role":122,"phone":123,"email":124},"Cheyanna Anderson","CONTACT","602-819-2380","Cheyanna.Anderson@commonspirit.org",{"lat":126,"lon":127},33.44838,-112.07404,{"facility":129,"status":8,"city":130,"state":131,"zip":132,"country":118,"contacts":133,"geoPoint":138},"Cedars Sinai Medical Center (Site #: 71146)","Beverly Hills","California","90211",[134],{"name":135,"role":122,"phone":136,"email":137},"Brian Gonzalez","310-423-8474","Bryan.Gonzalez@cshs.org",{"lat":139,"lon":140},34.07362,-118.40036,{"facility":142,"status":8,"city":143,"state":131,"zip":144,"country":118,"contacts":145,"geoPoint":150},"David Geffen School of Medicine at UCLA (Site #: 71123)","Los Angeles","90095",[146],{"name":147,"role":122,"phone":148,"email":149},"Paul Lopez, LVN","310-794-8595","plopez@mednet.ucla.edu",{"lat":151,"lon":152},34.05223,-118.24368,{"facility":154,"status":155,"city":156,"state":157,"zip":158,"country":118,"contacts":159,"geoPoint":164},"University of Florida Shands Hospital (Site #: 71131)","NOT_YET_RECRUITING","Gainesville","Florida","32610",[160],{"name":161,"role":122,"phone":162,"email":163},"Duncan Lewis","352-294-5195","duncan.lewis@medicine.ufl.edu",{"lat":165,"lon":166},29.65163,-82.32483,{"facility":168,"status":8,"city":169,"state":170,"zip":171,"country":118,"contacts":172,"geoPoint":177},"Emory University (Site #: 71103)","Atlanta","Georgia","55905",[173],{"name":174,"role":122,"phone":175,"email":176},"Shine Thomas","404-712-5137","sjthom5@emory.edu",{"lat":178,"lon":179},33.749,-84.38798,{"facility":181,"status":182,"city":183,"state":184,"zip":185,"country":118,"geoPoint":186},"University of Maryland Medical Center (Site #: 71138)","WITHDRAWN","Baltimore","Maryland","21201",{"lat":187,"lon":188},39.29038,-76.61219,{"facility":190,"status":8,"city":191,"state":192,"zip":193,"country":118,"contacts":194,"geoPoint":199},"Massachusetts General Hospital (Site #: 71107)","Boston","Massachusetts","02114",[195],{"name":196,"role":122,"phone":197,"email":198},"Idrisa Saad","617-726-1082","Isaad1@mgh.harvard.edu",{"lat":200,"lon":201},42.35843,-71.05977,{"facility":203,"status":182,"city":191,"state":192,"zip":204,"country":118,"geoPoint":205},"Boston Children's Hospital and Harvard Medical School (Site #: 71001)","02215",{"lat":200,"lon":201},{"facility":207,"status":155,"city":208,"state":209,"zip":171,"country":118,"contacts":210,"geoPoint":215},"Mayo Clinic Rochester (Site #: 71160)","Rochester","Minnesota",[211],{"name":212,"role":122,"phone":213,"email":214},"Julie Gecox Hanson","507-293-6592","gecox.julie@mayo.edu",{"lat":216,"lon":217},44.02163,-92.4699,{"facility":219,"status":8,"city":220,"state":221,"zip":222,"country":118,"contacts":223,"geoPoint":228},"Barnes Jewish Hospital\u002F Washington University SOM (Site #: 71191)","St Louis","Missouri","63110",[224],{"name":225,"role":122,"phone":226,"email":227},"Brigitte Mittler, CCRC","314-747-1931","b.mittler@wustl.edu",{"lat":229,"lon":230},38.62727,-90.19789,{"facility":232,"status":182,"city":220,"state":221,"zip":222,"country":118,"geoPoint":233},"St. Louis Children's Hospital of Washington University (Site #: 71006)",{"lat":229,"lon":230},{"facility":235,"status":8,"city":236,"state":236,"zip":237,"country":118,"contacts":238,"geoPoint":243},"Columbia University Medical Center (Site #: 71113)","New York","10032",[239],{"name":240,"role":122,"phone":241,"email":242},"Shreena Patel, BA, LPN","973-722-6835","sp3646@cumc.columbia.edu",{"lat":244,"lon":245},40.71427,-74.00597,{"facility":247,"status":8,"city":248,"state":249,"zip":250,"country":118,"contacts":251,"geoPoint":256},"Duke University Medical Center (Site #: 71139)","Durham","North Carolina","27710",[252],{"name":253,"role":122,"phone":254,"email":255},"Mary Motta","919-660-1355","mary.motta@duke.edu",{"lat":257,"lon":258},35.99403,-78.89862,{"facility":260,"status":8,"city":261,"state":262,"zip":263,"country":118,"contacts":264,"geoPoint":269},"Cleveland Clinic (Site #: 71101)","Cleveland","Ohio","44195",[265],{"name":266,"role":122,"phone":267,"email":268},"Abigail Camiener","216-390-5108","camiena3@ccf.org",{"lat":270,"lon":271},41.4995,-81.69541,{"facility":273,"status":8,"city":274,"state":262,"zip":275,"country":118,"contacts":276,"geoPoint":281},"Ohio State University Medical Center (Site #: 71196)","Columbus","43210",[277],{"name":278,"role":122,"phone":279,"email":280},"Benjamin Hood","614-293-4299","benjamin.hood2@osumc.edu",{"lat":282,"lon":283},39.96118,-82.99879,{"facility":285,"status":155,"city":286,"state":287,"zip":288,"country":118,"contacts":289,"geoPoint":294},"Temple University (Site #: 71197)","Philadelphia","Pennsylvania","19140",[290],{"name":291,"role":122,"phone":292,"email":293},"Nakeeda Earle","215-707-1359","Nakeeda.Earle@tuhs.temple.edu",{"lat":295,"lon":296},39.95238,-75.16362,{"facility":298,"status":8,"city":299,"state":300,"zip":301,"country":118,"contacts":302,"geoPoint":307},"Vanderbilt University (Site #: 71174)","Nashville","Tennessee","37232-0393",[303],{"name":304,"role":122,"phone":305,"email":306},"Briana Swanner","615-327-7232","briana.swanner@vumc.org",{"lat":308,"lon":309},36.16589,-86.78444,{"facility":311,"status":8,"city":312,"state":313,"zip":314,"country":118,"contacts":315,"geoPoint":320},"University of Texas Southwestern (Site #: 71187)","Dallas","Texas","75390",[316],{"name":317,"role":122,"phone":318,"email":319},"Alice Osuji","214-645-6605","alice.osuji@utsouthwestern.edu",{"lat":321,"lon":322},32.78306,-96.80667,{"facility":324,"status":182,"city":325,"state":313,"zip":326,"country":118,"geoPoint":327},"Houston Methodist Hospital (Site #: 71120)","Houston","77030",{"lat":328,"lon":329},29.76328,-95.36327,{"facility":331,"status":155,"city":332,"state":313,"zip":333,"country":118,"contacts":334,"geoPoint":338},"University of Texas Health Science at San Antonio (Site #: 71198)","San Antonio","78229",[335],{"name":336,"role":122,"email":337},"Renee Walruff","walruff@uthscsa.edu",{"lat":339,"lon":340},29.42412,-98.49363,{"facility":342,"status":8,"city":343,"state":344,"zip":345,"country":118,"contacts":346,"geoPoint":351},"University of Utah Medical Center (Site #: 71126)","Salt Lake City","Utah","84132",[347],{"name":348,"role":122,"phone":349,"email":350},"Julia Uddenberg, BS","(801) 646-6126","julia.uddenberg@hsc.utah.edu",{"lat":352,"lon":353},40.76078,-111.89105,[355],{"name":356,"role":122,"phone":357,"email":358},"Yvonne Morrison, MS","301-706-9137","ymorrison@niaid.nih.gov",[360,364,368],{"name":361,"affiliation":362,"role":363},"Joren Madsen, MD, D.Phil.","Massachusetts General Hospital","PRINCIPAL_INVESTIGATOR",{"name":365,"affiliation":366,"role":367},"Ramsey Hachem, MD","University of Utah Medical Center","STUDY_CHAIR",{"name":369,"affiliation":370,"role":367},"Daniel Kreisel, M.D.","Washington University School of Medicine",[],[373,375,378],{"label":13,"url":374},"https:\u002F\u002Fwww.niaid.nih.gov\u002F",{"label":376,"url":377},"Division of Allergy, Immunology, and Transplantation (DAIT)","https:\u002F\u002Fwww.niaid.nih.gov\u002Fabout\u002Fdait",{"label":379,"url":380},"NIAID Transplant Programs website","http:\u002F\u002Fwww.niaidtransplantstudies.org\u002F",{"nct_id":4,"conditions":382,"biomarkers":384},[383],"Lung Transplantation",[385],"IgG",{"nct_id":4,"found":15,"summary":387,"prompt_version":396},{"design":388,"status":389,"heading":6,"summary":390,"follow_up":391,"word_count":392,"commitments":393,"compensation":394,"drugs_mentioned":395},"This is an interventional study where 350 participants will be randomly assigned to receive either Tocilizumab or a placebo, in addition to standard medications. The phase of the study is not specified.","completed","This study is looking at whether adding Tocilizumab to standard medications can improve outcomes for people receiving a lung transplant. Researchers will compare Tocilizumab plus standard care to a placebo (a saline solution) plus standard care. You might be able to join if you are between 12 and 75 years old, weigh at least 30 kg, and are getting your first lung transplant. The study will enroll 350 participants. The main goal is to see if Tocilizumab can help prevent problems like chronic lung allograft dysfunction (CLAD), needing another transplant, or death within three years after your transplant. The current status of this study is unclear.","Participants will be followed for up to 36 months (3 years) after they are randomly assigned to a treatment group.",106,"If you participate, you would receive six doses of either Tocilizumab or placebo once every four weeks over a 20-week period. The first dose is given during your lung transplant surgery.","Not stated in the trial record.",[21],"v2"]